ProEthic Pharmaceuticals Report issue

For profit Phase 3
Founded: Montgomery AL United States (2001)
Status: Acquired by Kowa (2008)

Organization Overview

First Clinical Trial
2006
NCT00330850
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

pro-513 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperacusis (Phase 3)

Migraine Disorders (Phase 3)

Photophobia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1